AbCellera Biologics Inc vs Old Dominion Freight Line Inc — how do they compare? AbCellera Biologics Inc trades at $9.24 (market cap $2.85B), while Old Dominion Freight Line Inc trades at $209.64 (market cap $44.07B). The key difference: Old Dominion Freight Line Inc is far larger — about 15.5× AbCellera Biologics Inc's market cap, and Old Dominion Freight Line Inc pays a 0.55% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | ODFL | |
|---|---|---|
Market Cap | $2.85B | $44.07B |
Sector | Health | Industrials |
52-Week High | $9.76 | $248.73 |
52-Week Low | $2.78 | $126.29 |
Enterprise Value | $2.45B | $43.81B |
Dividend Yield | — | 0.55% |
Signals from Pluang's Aura AI — not financial advice
ABCL's stock surged 6.13% to $6.93, driven by positive Phase 2 trial results for its menopause drug ABCL635, which showed an 83% reduction in hot flashes. Despite a bullish technical signal and strong analyst consensus (91.67% buy ratings), the company faces fundamental challenges with a net income margin of -248.84% and negative cash flow from operations. Revenue declined from $485M in 2022 to $75M in 2025, though recent news highlights potential from clinical advancements and a collaboration with Vertex.
The outlook is mixed: near-term optimism hinges on drug development success, but high valuation ratios (P/S of 31.63) and persistent losses pose risks. Investors should weigh the 54% upside to the $10.67 price target against cash burn and competitive pressures in biotech.
ODFL stock trades at $216.36, up 2.34% today, with a bearish technical signal but strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $1.68 versus $1.54 expected, driven by yield improvements and cost discipline. The company maintains robust profitability with a net income margin of 19.44% and ROE of 24.82%, though revenue has declined from $6.3B in 2022 to $5.5B in 2025. Analyst consensus price target is $239.85, suggesting upside potential.
Outlook is mixed: earnings momentum and a solid balance sheet support growth, but high valuation ratios (P/E of 41.6) and freight volume pressures pose risks. Investors should weigh the premium pricing against operational efficiency gains and market recovery prospects.
Trailing returns across standard periods
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →Old Dominion Freight Line is the fourth-largest less-than-truckload carrier in the United States, with more than 240 service centers and 9,200-plus tractors. OD is by far one of the most disciplined and efficient providers in the trucking industry, and its profitability and capital returns stand head and shoulders above its peers. Strategic initiatives revolve around increasing network density through market share gains and maintaining industry-leading service via consistent infrastructure investment.
Read more on ODFL →